Ocular Therapeutix, Inc. has announced its participation in several key scientific and investor conferences throughout May 2026, highlighting its commitment to advancing retinal therapies. Notable presentations include the Phase 3 SOL-1 trial results for Axitinib Hydrogel (OTX-TKI) in neovascular age-related macular degeneration (nAMD), which will be discussed at the ARVO 2026 Annual Meeting on May 5, 2026. This investigational therapy utilizes a proprietary bioresorbable hydrogel formulation aimed at enhancing drug delivery and therapeutic efficacy.

The significance of Ocular’s findings lies in the promising data emerging from the ongoing clinical trials, particularly for wet AMD and diabetic retinal diseases. The use of axitinib, a potent tyrosine kinase inhibitor, in a hydrogel format may offer improved sustained drug release and patient compliance, potentially transforming treatment paradigms in retinal disease management. The presentations at these conferences will not only disseminate critical data but also foster discussions on the implications of sustained disease control and treatment durability.

The implications for the field are substantial, as Ocular’s advancements could accelerate the development timelines for new therapies targeting retinal diseases. The integration of ELUTYX™ technology in both investigational and commercial products positions Ocular as a leader in innovative drug delivery systems. This focus on enhancing therapeutic outcomes through novel formulations may set new standards for clinical practice in ophthalmology, driving further research and investment in similar approaches across the longevity and aging biology sectors.

Source: globenewswire.com